Method for treatment of cytokine release syndrome
A composition for preventing and/or treating cytokine release syndrome and a method of prevention and/or treatment of cytokine release syndrome are disclosed. The composition includes an aryl ethene compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, as an active ingredient. The method includes administering the aryl ethene compound, an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof, in an effective amount to a subject in need thereof. The cytokine release syndrome may be caused by virulent infection. The administration of the compound reduces the pre-inflammatory cytokine levels in the subject.
1. A method for treating or managing cytokine release syndrome in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the following compounds:
or an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof,
wherein the cytokine release syndrome is caused by an acute inflammatory disorder or virulent infection, and
wherein the treating or managing cytokine release syndrome comprises reducing a level of a cytokine in serum of the subject.
2. The method of claim 1 , wherein the infection is a viral infection.
3. The method of claim 1 , wherein the inflammatory disorder is sepsis.
4. The method claim 1 , wherein the inflammatory disorder is pneumonia.
5. The method of claim 1 , wherein the cytokine is IFNb, IL1b, TNFa, and/or IL6.
6. The method of claim 1 , wherein the compound is (E)-5-(4-hydroxyphenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol of the following chemical formula:
or an isomer, a pharmaceutically acceptable salt, or a solvate thereof.
7. The method of claim 6 , wherein the cytokine release syndrome is induced by viral infection.
8. A method for diminishing supraphysiological levels of one or more selected from the group consisting of IFNb, IL1b, TNFa, and IL6 in a subject in need thereof, comprising administering to the subject an effective amount of a compound selected from the following compounds:
or an isomer, a pharmaceutically acceptable salt thereof, or a solvate thereof,
wherein the subject suffers from a virulent infection or acute inflammatory disorder.
9. The method of claim 8 , wherein the compound of Chemical Formula 1 is (E)-5-(4-hydroxyphenyl)-5-(4-(4-isopropylpiperazin-1-yl)phenyl)-4-phenylpent-4-en-1-ol of the following chemical formula: